Terns Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1065 E Hillsdale Blvd Ste 100, Foster Ci...Phone Number
(650) 525-5535Website
www.ternspharma.comRevenue
-Stock Symbol
TERNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR- agonist and preclinical GIPR modulator programs. For more information, please visit: www.ternspharma.com.Explore more
Terns Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Terns Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Terns Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Terns Pharmaceuticals
Check out if Terns Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Terns Pharmaceuticals recently announced quarterly report
Click to see if Terns Pharmaceuticals had a recent Job posting/layoffs
Terns Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Terns Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Terns Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Terns Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Terns Pharmaceuticals
Compare insights from companies similar to Terns Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Terns Pharmaceuticals
51-200
Public
$197M
2016
Andrew GengosChief Financial Officer & Head of Corporate Development
Company Profile Activity
Activity Insights
Terns Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Terns Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Terns Pharmaceuticals.
Terns Pharmaceuticals financials insights
Gather financial insights about Terns Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$30M
Series B
$80M
2021
Series C
$87M
Terns Pharmaceuticals Tech Stack
A closer look at the technologies used by Terns Pharmaceuticals
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
reported that TERN-701 is already showing higher MMR rates in third line+ chronic myeloid leukemia patients than asciminib's front line confidence interval of around 60%, giving confidence for strong front line performance.
Medical Research, Pharmaceuticals
Project
Terns Pharmaceuticals is strongly leaning toward including asciminib in the control arm of the front-line TERN-701 study alongside imatinib and 2G-TKIs, as asciminib did not show statistically significantly superior efficacy to the 2G-TKI strata alone in the ASC4FIRST study.
Medical Research, Pharmaceuticals, Clinical Operations
Event
Person-Based
Events, Product Development, Pharmaceuticals, Corporate Strategy, Podcast
Terns Pharmaceuticals News & Media
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs) Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase (CP) without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs)Why Terns Pharmaceuticals Stock Rocked the Market in March
A large peer is snapping up the company in a premium-priced deal.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Terns Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR... Read More
